{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T08:39:54Z","timestamp":1771231194784,"version":"3.50.1"},"reference-count":132,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Steroids"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.steroids.2022.109102","type":"journal-article","created":{"date-parts":[[2022,8,24]],"date-time":"2022-08-24T11:14:49Z","timestamp":1661339689000},"page":"109102","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Corticosteroids: A boon or bane for COVID-19 patients?"],"prefix":"10.1016","volume":"188","author":[{"given":"Subhadeep","family":"Sen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhagat","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Goutam","family":"Biswas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.steroids.2022.109102_b0005","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41591-020-0820-9","article-title":"The proximal origin of SARS-CoV-2","volume":"26","author":"Andersen","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0010","unstructured":"WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) Dashboard With Vaccination Data, (n.d.). https:\/\/covid19.who.int\/ (accessed May 8, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0015","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.healun.2020.03.012","article-title":"COVID-19 illness in native and immunosuppressed states: a clinical\u2013therapeutic staging proposal","volume":"39","author":"Siddiqi","year":"2020","journal-title":"J. Heart Lung Transplant."},{"key":"10.1016\/j.steroids.2022.109102_b0020","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1038\/s41418-020-0530-3","article-title":"COVID-19 infection: the perspectives on immune responses","volume":"27","author":"Shi","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.steroids.2022.109102_b0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108427","article-title":"COVID-19 pathophysiology: A review","volume":"215","author":"Yuki","year":"2020","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.steroids.2022.109102_b0030","doi-asserted-by":"crossref","unstructured":"R.B. Polidoro, R.S. Hagan, R. de Santis Santiago, N.W. Schmidt, Overview: Systemic Inflammatory Response Derived From Lung Injury Caused by SARS-CoV-2 Infection Explains Severe Outcomes in COVID-19, Front. Immunol. 11 (2020) 1626. https:\/\/doi.org\/10.3389\/fimmu.2020.01626.","DOI":"10.3389\/fimmu.2020.01626"},{"key":"10.1016\/j.steroids.2022.109102_b0035","doi-asserted-by":"crossref","first-page":"4536","DOI":"10.2174\/0929867327666200416131117","article-title":"SARS-CoV-2: recent reports on antiviral therapies based on lopinavir\/ritonavir, darunavir\/umifenovir, hydroxychloroquine, remdesivir, favipiravir and other drugs for the treatment of the new coronavirus","volume":"27","author":"Costanzo","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.steroids.2022.109102_b0040","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.2174\/1389557521666201222145842","article-title":"Repurposed antiviral drugs for the treatment of COVID-19: syntheses, mechanism of infection and clinical trials","volume":"21","author":"Paul","year":"2021","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.steroids.2022.109102_b0045","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2020.1023","article-title":"COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?","volume":"14","author":"Russell","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.steroids.2022.109102_b0050","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.635371","article-title":"Lack of effectiveness of repurposed drugs for COVID-19 treatment","volume":"12","author":"Martinez","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.steroids.2022.109102_b0055","doi-asserted-by":"crossref","first-page":"704","DOI":"10.2174\/1389557520666201113105940","article-title":"Drug re-purposing approach and potential therapeutic strategies to treat COVID-19","volume":"21","author":"Reddy","year":"2021","journal-title":"Mini-Rev. Med. Chem."},{"key":"10.1016\/j.steroids.2022.109102_b0060","doi-asserted-by":"crossref","unstructured":"Repurposed Antiviral Drugs for Covid-19 \u2014 Interim WHO Solidarity Trial Results, N. Engl. J. Med. 384 (2021) 497\u2013511. doi: 10.1056\/NEJMoa2023184.","DOI":"10.1056\/NEJMoa2023184"},{"issue":"1","key":"10.1016\/j.steroids.2022.109102_b0065","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40199-022-00441-z","article-title":"Design, synthesis and docking study of Vortioxetine derivatives as a SARS-CoV-2 main protease inhibitor","volume":"30","author":"Suryavanshi","year":"2022","journal-title":"DARU J. Pharm. Sci."},{"key":"10.1016\/j.steroids.2022.109102_b0070","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1016\/j.apsb.2021.06.016","article-title":"Recent advances in developing small-molecule inhibitors against SARS-CoV-2","volume":"12","author":"Xiang","year":"2022","journal-title":"Acta Pharm. Sin. B."},{"issue":"4","key":"10.1016\/j.steroids.2022.109102_b0075","doi-asserted-by":"crossref","first-page":"e0249481","DOI":"10.1371\/journal.pone.0249481","article-title":"The proportion and effect of corticosteroid therapy in patients with COVID-19 infection: A systematic review and meta-analysis","volume":"16","author":"Wang","year":"2021","journal-title":"PLOS ONE"},{"key":"10.1016\/j.steroids.2022.109102_b0080","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S2213-2600(20)30076-X","article-title":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome","volume":"8","author":"Xu","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0085","doi-asserted-by":"crossref","unstructured":"N. Arain, S.C. Paravastu, M.A. Arain, Effectiveness of topical corticosteroids in addition to antiviral therapy in the management of recurrent herpes labialis: a systematic review and meta-analysis, BMC Infect. Dis. 15 (2015) 82. doi: 10.1186\/s12879-015-0824-0.","DOI":"10.1186\/s12879-015-0824-0"},{"key":"10.1016\/j.steroids.2022.109102_b0090","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1471-2377-11-1","article-title":"Corticosteroid and antiviral therapy for Bell\u2019s palsy: a network meta-analysis","volume":"11","author":"Numthavaj","year":"2011","journal-title":"BMC Neurol."},{"key":"10.1016\/j.steroids.2022.109102_b0095","doi-asserted-by":"crossref","first-page":"35","DOI":"10.3390\/chemengineering2030035","article-title":"Evaluation of Cd(II) ion removal from aqueous solution by a low-cost adsorbent prepared from white yam (Dioscorea rotundata) waste using batch sorption","volume":"2","author":"Asuquo","year":"2018","journal-title":"ChemEngineering"},{"key":"10.1016\/j.steroids.2022.109102_b0100","doi-asserted-by":"crossref","first-page":"11022","DOI":"10.1038\/s41598-021-90551-6","article-title":"The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials","volume":"11","author":"Hassanipour","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.steroids.2022.109102_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.606429","article-title":"Mortality benefit of remdesivir in COVID-19: a systematic review and meta-analysis","volume":"7","author":"Bansal","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0110","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1056\/NEJMoa2035002","article-title":"REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0115","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0120","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/S0140-6736(21)01380-5","article-title":"Tocilizumab in COVID-19 therapy: who benefits, and how?","volume":"398","author":"Yang","year":"2021","journal-title":"The Lancet"},{"issue":"1","key":"10.1016\/j.steroids.2022.109102_b0125","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1007\/s11606-021-07146-0","article-title":"The use of corticosteroids or tocilizumab in COVID-19 based on inflammatory markers","volume":"37","author":"Rubio-Rivas","year":"2022","journal-title":"J Gen Intern Med"},{"issue":"1","key":"10.1016\/j.steroids.2022.109102_b0130","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.jointm.2021.01.002","article-title":"Corticosteroids for COVID-19","volume":"1","author":"Annane","year":"2021","journal-title":"J. Intensive Med."},{"key":"10.1016\/j.steroids.2022.109102_b0135","first-page":"358","article-title":"SARS-CoV-2: the path of prevention and control","volume":"21","author":"Mohamed","year":"2021","journal-title":"infect. Disord. \u2013 Drug Targets"},{"key":"10.1016\/j.steroids.2022.109102_b0140","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1172\/JCI140617","article-title":"Corticosteroid treatment in severe COVID-19 patients with acute respiratory distress syndrome","volume":"130","author":"Liu","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.steroids.2022.109102_b0145","doi-asserted-by":"crossref","first-page":"20935","DOI":"10.1038\/s41598-020-78054-2","article-title":"A systematic review of corticosteroid treatment for noncritically ill patients with COVID-19","volume":"10","author":"Shuto","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/j.steroids.2022.109102_b0150","article-title":"Systemic corticosteroids for the treatment of COVID-19","volume":"2021","author":"Wagner","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.steroids.2022.109102_b0155","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2020.596587","article-title":"The need for antiviral drugs for pandemic coronaviruses from a global health perspective","volume":"7","author":"Villamagna","year":"2020","journal-title":"Front. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0160","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s12879-022-07068-0","article-title":"Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials","volume":"22","author":"Vegivinti","year":"2022","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.steroids.2022.109102_b0165","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s42399-021-00824-4","article-title":"Tocilizumab, remdesivir, favipiravir, and dexamethasone repurposed for COVID-19: a comprehensive clinical and pharmacovigilant reassessment","volume":"3","author":"Kelleni","year":"2021","journal-title":"SN Compr. Clin. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0170","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.ijid.2020.10.069","article-title":"Role of favipiravir in the treatment of COVID-19","volume":"102","author":"Joshi","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.steroids.2022.109102_b0175","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1016\/j.cmi.2021.12.026","article-title":"Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial","volume":"28","author":"Bosaeed","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"issue":"10","key":"10.1016\/j.steroids.2022.109102_b0180","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/bph.15452","article-title":"Therapeutic strategies to fight COVID-19: Which is the status artis ?","volume":"179","author":"Scavone","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.steroids.2022.109102_b0185","doi-asserted-by":"crossref","DOI":"10.4269\/ajtmh.21-0606","article-title":"Remdesivir efficacy in COVID-19 treatment: a randomized controlled trial","author":"Abd-Elsalam","year":"2021","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"10.1016\/j.steroids.2022.109102_b0190","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.2174\/1568026620999200517043137","article-title":"Novel drugs targeting the SARS-CoV-2\/COVID-19 machinery","volume":"20","author":"Sternberg","year":"2020","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.steroids.2022.109102_b0195","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.ijid.2021.01.065","article-title":"Remdesivir and systemic corticosteroids for the treatment of COVID-19: a Bayesian re-analysis","volume":"104","author":"Lee","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"10.1016\/j.steroids.2022.109102_b0200","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.632677","article-title":"An update on antiviral therapy against SARS-CoV-2: how far have we come?","volume":"12","author":"Indari","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.steroids.2022.109102_b0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.cegh.2020.07.011","article-title":"Remdesivir and its antiviral activity against COVID-19: a systematic review","volume":"9","author":"Frediansyah","year":"2021","journal-title":"Clin. Epidemiol. Glob. Health."},{"issue":"1","key":"10.1016\/j.steroids.2022.109102_b0210","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-020-19761-2","article-title":"Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report","volume":"11","author":"Buckland","year":"2020","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.steroids.2022.109102_b0215","doi-asserted-by":"crossref","first-page":"3949","DOI":"10.1016\/j.cell.2021.06.002","article-title":"The monoclonal antibody combination REGEN-COV protects against SARS-CoV-2 mutational escape in preclinical and human studies","volume":"184","author":"Copin","year":"2021","journal-title":"Cell."},{"key":"10.1016\/j.steroids.2022.109102_b0220","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41577-021-00542-x","article-title":"Neutralizing monoclonal antibodies for treatment of COVID-19","volume":"21","author":"Taylor","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.steroids.2022.109102_b0225","article-title":"Compassionate use of REGN-COV2 in the treatment of COVID-19 in a patient with impaired humoral immunity","volume":"12","author":"Nguyen","year":"2021","journal-title":"Clin. Infect. Pract."},{"issue":"3","key":"10.1016\/j.steroids.2022.109102_b0230","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1007\/s15010-022-01779-x","article-title":"High titer of antibody against the SARS-CoV-2 spike protein among patients receiving neutralizing antibody cocktail therapy with REGN-COV","volume":"50","author":"Sasaki","year":"2022","journal-title":"Infection"},{"key":"10.1016\/j.steroids.2022.109102_b0235","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.620187","article-title":"Tocilizumab in COVID-19: factors associated with mortality before and after treatment","volume":"12","author":"Sarabia De Ardanaz","year":"2021","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.steroids.2022.109102_b0240","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.pulmoe.2020.07.003","article-title":"Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review","volume":"27","author":"Cortegiani","year":"2021","journal-title":"Pulmonology"},{"key":"10.1016\/j.steroids.2022.109102_b0245","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1080\/14712598.2021.1880563","article-title":"Tocilizumab for the treatment of COVID-19","volume":"21","author":"Fern\u00e1ndez-Ruiz","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.steroids.2022.109102_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2020.107018","article-title":"Tocilizumab for treatment patients with COVID-19: Recommended medication for novel disease","volume":"89","author":"Samaee","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.steroids.2022.109102_b0255","unstructured":"Remdesivir Uses, Side Effects & Warnings - Drugs.com, (n.d.). https:\/\/www.drugs.com\/mtm\/remdesivir.html (accessed November 10, 2021)."},{"key":"10.1016\/j.steroids.2022.109102_b0260","unstructured":"Favipiravir (United States: Not commercially available; refer to Prescribing and Access Restrictions): Drug information \u2013 UpToDate, (n.d.). https:\/\/www.uptodate.com\/contents\/favipiravir-united-states-not-commercially-available-refer-to-prescribing-and-access-restrictions-drug-information\/print (accessed November 10, 2021)."},{"key":"10.1016\/j.steroids.2022.109102_b0265","unstructured":"Casirivimab and Imdevimab, (n.d.). https:\/\/www.regeneron.com\/medicines\/casirivimab-imdevimab (accessed November 10, 2021)."},{"key":"10.1016\/j.steroids.2022.109102_b0270","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1007\/s42399-020-00610-8","article-title":"Dexamethasone for the Treatment of Coronavirus Disease (COVID-19): a Review","volume":"2","author":"Ahmed","year":"2020","journal-title":"SN Compr. Clin. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0275","unstructured":"Dexamethasone | C22H29FO5 - PubChem, (n.d.). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5743 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0280","unstructured":"Methylprednisolone | C22H30O5 - PubChem, (n.d.). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/6741 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0285","unstructured":"Prednisolone | C21H28O5 - PubChem, (n.d.). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5755 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0290","unstructured":"Hydrocortisone | C21H30O5 - PubChem, (n.d.). https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/5754 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0295","doi-asserted-by":"crossref","unstructured":"I. Herr\u00e1iz, Chemical Pathways of Corticosteroids, Industrial Synthesis from Sapogenins, in: 2017: pp. 15\u201327. doi: 10.1007\/978-1-4939-7183-1_2.","DOI":"10.1007\/978-1-4939-7183-1_2"},{"key":"10.1016\/j.steroids.2022.109102_b0300","doi-asserted-by":"crossref","unstructured":"R.S. Vardanyan, V.J. Hruby, Corticosteroids, in: Synth. Essent. Drugs, Elsevier, 2006: pp. 349\u2013363. doi: 10.1016\/B978-044452166-8\/50027-3.","DOI":"10.1016\/B978-044452166-8\/50027-3"},{"key":"10.1016\/j.steroids.2022.109102_b0305","doi-asserted-by":"crossref","first-page":"4223","DOI":"10.1021\/ja01137a001","article-title":"The Total Synthesis of Steroids 1","volume":"74","author":"Woodward","year":"1952","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2022.109102_b0310","doi-asserted-by":"crossref","first-page":"4974","DOI":"10.1021\/ja01139a532","article-title":"Stereospecific total synthesis of cortisone","volume":"74","author":"Sarett","year":"1952","journal-title":"J. Am. Chem. Soc."},{"issue":"2","key":"10.1016\/j.steroids.2022.109102_b0315","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1021\/ja01098a049","article-title":"Approaches to the total synthesis of adrenal steroids. 1 V. 4b-Methyl-7- ethylenedioxy-1,2,3,4,4a\u03b1,4b,5,6,7,8,10,10a \u03b2-dodecahydrophenanthrene-4 \u03b2-ol-1-one and related tricyclic derivatives","volume":"75","author":"Poos","year":"1953","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2022.109102_b0320","doi-asserted-by":"crossref","first-page":"4110","DOI":"10.1021\/ja01112a535","article-title":"A synthesis of dl-cortisone acetate","volume":"75","author":"Barkley","year":"1953","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2022.109102_b0325","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/j.2042-7158.1953.tb14005.x","article-title":"The chemistry of cortisone","volume":"5","author":"Hems","year":"2011","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.steroids.2022.109102_b0330","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1002\/ange.19600721903","article-title":"Neuere Ergebnisse bei der Totalsynthese von Steroiden","volume":"72","author":"Velluz","year":"1960","journal-title":"Angew. Chem."},{"key":"10.1016\/j.steroids.2022.109102_b0335","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1351\/pac196306040525","article-title":"Progress in the total synthesis of steroids","volume":"6","author":"Torgov","year":"1963","journal-title":"Pure Appl. Chem."},{"key":"10.1016\/j.steroids.2022.109102_b0340","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt775","article-title":"Total biosynthesis of hydrocortisone from a simple carbon source in yeast","volume":"21","author":"Szczebara","year":"2003","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.steroids.2022.109102_b0345","doi-asserted-by":"crossref","unstructured":"Synthesis of Dexamethasone, Synfacts. 16 (2020) 1027. doi: 10.1055\/s-0040-1705869.","DOI":"10.1055\/s-0040-1705869"},{"key":"10.1016\/j.steroids.2022.109102_b0350","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/slct.202100127","article-title":"COVID-19 into chemical science perspective: chemical preventive measures and drug development","volume":"6","author":"Adhikari","year":"2021","journal-title":"ChemistrySelect."},{"key":"10.1016\/j.steroids.2022.109102_b0355","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1021\/op9700338","article-title":"Improved synthetic route to dexamethasone acetate from tigogenin","volume":"1","author":"Ohta","year":"1997","journal-title":"Org. Process Res. Dev."},{"key":"10.1016\/j.steroids.2022.109102_b0360","doi-asserted-by":"crossref","first-page":"4436","DOI":"10.1021\/ja01621a092","article-title":"The adrenal hormones and related compounds. I. A \u201cdirect\u201d synthesis of hydrocortisone acetate and cortisone acetate from 11\u03b1-hydroxyprogesterone","volume":"77","author":"Hogg","year":"1955","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2022.109102_b0365","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/0005-2760(78)90213-8","article-title":"Bioconversion of sitosterol to useful steroidal intermediates by mutants of Mycobacterium fortuitum","volume":"531","author":"Wovcha","year":"1978","journal-title":"Biochim. Biophys. Acta BBA \u2013 Lipids Lipid Metab."},{"key":"10.1016\/j.steroids.2022.109102_b0370","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1246\/bcsj.58.978","article-title":"The syntheses of the corticoid side chain. I. An improved method for the preparation of 17\u03b1-hydroxyprogesterone from androst-4-ene-3,17-dione","volume":"58","author":"Nitta","year":"1985","journal-title":"Bull. Chem. Soc. Jpn."},{"key":"10.1016\/j.steroids.2022.109102_b0375","doi-asserted-by":"crossref","unstructured":"I. Herr\u00e1iz, Chemical Pathways of Corticosteroids, Industrial Synthesis from Sapogenins, in: J.-L. Barredo, I. Herr\u00e1iz (Eds.), Microb. Steroids, Springer New York, New York, NY, 2017: pp. 15\u201327. doi: 10.1007\/978-1-4939-7183-1_2.","DOI":"10.1007\/978-1-4939-7183-1_2"},{"key":"10.1016\/j.steroids.2022.109102_b0380","doi-asserted-by":"crossref","first-page":"6213","DOI":"10.1021\/ja01604a078","article-title":"Adrenal hormones and related compounds. iv. 6-methyl steroids 1","volume":"78","author":"Spero","year":"1956","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2022.109102_b0385","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1021\/ja01563a075","article-title":"Adrenal hormones and related compounds. V. Fluorinated 6-methyl steroids","volume":"79","author":"Spero","year":"1957","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2022.109102_b0390","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/ja01514a055","article-title":"Alkylated adrenal hormones. The synthesis of 6\u03b1-methyl cortical steroids","volume":"81","author":"Fried","year":"1959","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.steroids.2022.109102_b0395","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/nri.2017.1","article-title":"Immune regulation by glucocorticoids","volume":"17","author":"Cain","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.steroids.2022.109102_b0400","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.vetimm.2008.10.303","article-title":"Genomic and non-genomic effects of dexamethasone on equine peripheral blood neutrophils","volume":"128","author":"Lecoq","year":"2009","journal-title":"Vet. Immunol. Immunopathol."},{"key":"10.1016\/j.steroids.2022.109102_b0405","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/j.1749-6632.2002.tb04200.x","article-title":"Mechanisms of Corticosteroid Resistance in Rheumatoid Arthritis","volume":"966","author":"Chikanza","year":"2002","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.steroids.2022.109102_b0410","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/348166a0","article-title":"Reduced levels of hsp90 compromise steroid receptor action in vivo","volume":"348","author":"Picard","year":"1990","journal-title":"Nature."},{"key":"10.1016\/j.steroids.2022.109102_b0415","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1101\/gad.827900","article-title":"The glucocorticoid receptor inhibits NF\u03baB by interfering with serine-2 phosphorylation of the RNA polymerase II carboxy-terminal domain","volume":"14","author":"Nissen","year":"2000","journal-title":"Genes Dev."},{"key":"10.1016\/j.steroids.2022.109102_b0420","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1101\/gad.1297105","article-title":"The glucocorticoid receptor blocks P-TEFb recruitment by NF\u03baB to effect promoter-specific transcriptional repression","volume":"19","author":"Luecke","year":"2005","journal-title":"Genes Dev."},{"key":"10.1016\/j.steroids.2022.109102_b0425","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/sj.emboj.7600919","article-title":"The GRIP1:IRF3 interaction as a target for glucocorticoid receptor-mediated immunosuppression","volume":"25","author":"Reily","year":"2006","journal-title":"EMBO J."},{"key":"10.1016\/j.steroids.2022.109102_b0430","doi-asserted-by":"crossref","first-page":"3773","DOI":"10.3390\/ijms22073773","article-title":"Corticosteroids for COVID-19 therapy: potential implications on tuberculosis","volume":"22","author":"Gopalaswamy","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.steroids.2022.109102_b0435","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1182\/blood-2002-02-0538","article-title":"Synthesis of glucocorticoid-induced leucine zipper (GILZ) by macrophages: an anti-inflammatory and immunosuppressive mechanism shared by glucocorticoids and IL-10","volume":"101","author":"Berrebi","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.steroids.2022.109102_b0440","doi-asserted-by":"crossref","first-page":"7802","DOI":"10.1128\/MCB.22.22.7802-7811.2002","article-title":"Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38","volume":"22","author":"Lasa","year":"2002","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.steroids.2022.109102_b0445","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0091-6749(98)70196-4","article-title":"Glucocorticoids inhibit chemokine generation by human eosinophils","volume":"101","author":"Miyamasu","year":"1998","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.steroids.2022.109102_b0450","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1165\/ajrcmb.21.4.3660","article-title":"Expression of monocyte chemotactic protein (MCP)-1, MCP-2, and MCP-3 by human airway smooth-muscle cells: modulation by corticosteroids and T-helper 2 cytokines","volume":"21","author":"Pype","year":"1999","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.steroids.2022.109102_b0455","doi-asserted-by":"crossref","first-page":"9991","DOI":"10.1073\/pnas.89.21.9991","article-title":"A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1","volume":"89","author":"Cronstein","year":"1992","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.steroids.2022.109102_b0460","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/0024-3205(79)90323-0","article-title":"Rescue of a positive stranded RNA virus from antigen negative neuroblastoma cells","volume":"24","author":"Stohlman","year":"1979","journal-title":"Life Sci."},{"key":"10.1016\/j.steroids.2022.109102_b0465","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.3389\/fimmu.2018.01736","article-title":"Immune effects of corticosteroids in sepsis","volume":"9","author":"Heming","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.steroids.2022.109102_b0470","doi-asserted-by":"crossref","first-page":"9573","DOI":"10.1073\/pnas.160099797","article-title":"Inhibition of IL-2-induced Jak-STAT signaling by glucocorticoids","volume":"97","author":"Bianchi","year":"2000","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.steroids.2022.109102_b0475","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4049\/jimmunol.1002485","article-title":"Glucocorticosteroids modify langerhans cells to produce TGF-\u03b2 and expand regulatory T cells","volume":"186","author":"Stary","year":"2011","journal-title":"J. Immunol."},{"key":"10.1016\/j.steroids.2022.109102_b0480","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1111\/j.1365-2222.2004.01824.x","article-title":"Glucocorticoids up-regulate constitutive interleukin-10 production by human monocytes","volume":"34","author":"Mozo","year":"2004","journal-title":"Clin. Htmlent Glyphamp Asciiamp Exp. Allergy."},{"key":"10.1016\/j.steroids.2022.109102_b0485","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.3389\/fimmu.2019.02028","article-title":"More than suppression: glucocorticoid action on monocytes and macrophages","volume":"10","author":"Ehrchen","year":"2019","journal-title":"Front. Immunol."},{"key":"10.1016\/j.steroids.2022.109102_b0490","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2006.08.027","article-title":"The anti-inflammatory effect of glucocorticoids is mediated by glucocorticoid-induced leucine zipper in epithelial cells","volume":"119","author":"Eddleston","year":"2007","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.steroids.2022.109102_b0495","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S2665-9913(20)30120-X","article-title":"The immunology of COVID-19: is immune modulation an option for treatment?","volume":"2","author":"Zhong","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"10.1016\/j.steroids.2022.109102_b0500","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1186\/s13054-020-03400-9","article-title":"Corticosteroid use in COVID-19 patients: a systematic review and meta-analysis on clinical outcomes","volume":"24","author":"van Paassen","year":"2020","journal-title":"Crit. Care."},{"key":"10.1016\/j.steroids.2022.109102_b0505","unstructured":"Corticosteroids for COVID-19, (n.d.). https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-Corticosteroids-2020.1 (accessed August 1, 2021)."},{"key":"10.1016\/j.steroids.2022.109102_b0510","unstructured":"Corticosteroids | COVID-19 Treatment Guidelines, (n.d.). https:\/\/www.covid19treatmentguidelines.nih.gov\/therapies\/immunomodulators\/corticosteroids\/ (accessed November 10, 2021)."},{"issue":"10303","key":"10.1016\/j.steroids.2022.109102_b0515","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/S0140-6736(21)01744-X","article-title":"Inhaled budesonide for COVID-19 in people at high risk of complications in the community in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial","volume":"398","author":"Yu","year":"2021","journal-title":"The Lancet"},{"issue":"7","key":"10.1016\/j.steroids.2022.109102_b0520","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/S2213-2600(21)00160-0","article-title":"Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial","volume":"9","author":"Ramakrishnan","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0525","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1016\/S2213-2600(21)00076-X","article-title":"COVID-19 and inhaled corticosteroids\u2014another piece in an expanding puzzle","volume":"9","author":"Schultze","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0530","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/S2213-2600(20)30314-3","article-title":"Inhaled corticosteroids in virus pandemics: a treatment for COVID-19?","volume":"8","author":"Nicolau","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.steroids.2022.109102_b0535","unstructured":"Dexamethasone for COVID-19 Related ARDS: a Multicenter, Randomized Clinical Trial \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04395105 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0540","unstructured":"COVID-19-associated ARDS Treated With Dexamethasone: Alliance Covid-19 Brasil III \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04327401 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0545","unstructured":"Dexamethasone and Oxygen Support Strategies in ICU Patients With Covid-19 Pneumonia \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04344730 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0550","unstructured":"Dexamethasone for COVID-19 - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04707534 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0555","unstructured":"Comparison Between Prednisolone and Dexamethasone on Mortality in Patients on Oxygen Therapy, With CoViD-19 \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04765371 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0560","unstructured":"Impact of Steroids on Inflammatory Response in Covid-19 \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04909918 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0565","unstructured":"The Efficacy of Different Hormone Doses in 2019-nCoV Severe Pneumonia \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04263402 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0570","unstructured":"Investigating the efficacy of high dose of glucocorticoid in patients with moderate to severe pneumonia related to COVID-19 | IRCT; 2020-05-05; TrialID: IRCT20080901001165N52 | ICTRP, (n.d.). https:\/\/search.bvsalud.org\/global-literature-on-novel-coronavirus-2019-ncov\/resource\/en\/ictrp-IRCT20080901001165N52 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0575","unstructured":"IRCT | Evaluation of Methylprednisolone Administration as a Therapeutic Option in the Coronavirus disease 2019 (COVID-19): A Randomized Controlled Study, (n.d.). https:\/\/www.irct.ir\/trial\/46776 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0580","unstructured":"Methylprednisolone in the Treatment of Patients With Signs of Severe Acute Respiratory Syndrome in Covid-19 - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04343729 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0585","unstructured":"Glucocorticoids in COVID-19 (CORTIVID) \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04438980 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0590","unstructured":"Hydrocortisone for COVID-19 and Severe Hypoxia \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04348305 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0595","unstructured":"Efficacy and Safety of Corticosteroids in Oxygen-dependent Patients With COVID-19 Pneumonia \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04359511 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0600","unstructured":"Inhaled Corticosteroid Treatment of COVID19 Patients With Pneumonia \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04355637 (accessed July 27, 2022)."},{"key":"10.1016\/j.steroids.2022.109102_b0605","unstructured":"Inhaled Ciclesonide for Outpatients With COVID19 \u2013 Full Text View \u2013 ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04435795 (accessed July 27, 2022)."},{"issue":"2","key":"10.1016\/j.steroids.2022.109102_b0610","doi-asserted-by":"crossref","first-page":"e0264301","DOI":"10.1371\/journal.pone.0264301","article-title":"Comparative outcomes of combined corticosteroid and remdesivir therapy with corticosteroid monotherapy in ventilated COVID-19 patients","volume":"17","author":"Mandadi","year":"2022","journal-title":"PLOS ONE"},{"key":"10.1016\/j.steroids.2022.109102_b0615","doi-asserted-by":"crossref","unstructured":"Y. Shionoya, T. Taniguchi, H. Kasai, N. Sakuma, S. Imai, K. Shikano, S. Takayanagi, M. Yahaba, T. Nakada, H. Igari, S. Sakao, T. Suzuki, Possibility of deterioration of respiratory status when steroids precede antiviral drugs in patients with COVID-19 pneumonia: a retrospective study, PLOS ONE. 16 (2021) e0256977. doi: 10.1371\/journal.pone.0256977.","DOI":"10.1371\/journal.pone.0256977"},{"key":"10.1016\/j.steroids.2022.109102_b0620","doi-asserted-by":"crossref","first-page":"ofaa486","DOI":"10.1093\/ofid\/ofaa486","article-title":"Antivirals with adjunctive corticosteroids prevent clinical progression of early coronavirus 2019 pneumonia: a retrospective cohort study","volume":"7","author":"Ooi","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"10.1016\/j.steroids.2022.109102_b0625","article-title":"Combination treatment of short-course systemic corticosteroid and favipiravir in a successfully treated case of critically ill COVID-19 pneumonia with COPD","volume":"31","author":"Inoue","year":"2020","journal-title":"Respir. Med. Case Rep."},{"key":"10.1016\/j.steroids.2022.109102_b0630","unstructured":"Hospitalized Adults: Therapeutic Management | COVID-19 Treatment Guidelines, (n.d.). https:\/\/www.covid19treatmentguidelines.nih.gov\/management\/clinical-management\/hospitalized-adults--therapeutic-management\/ (accessed November 10, 2021)."},{"key":"10.1016\/j.steroids.2022.109102_b0635","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1002\/jmv.27489","article-title":"Combination therapy of tocilizumab and steroid for COVID-19 patients: a meta-analysis","volume":"94","author":"Moosazadeh","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.steroids.2022.109102_b0640","unstructured":"Ivermectin, Aspirin, Dexamethasone and Enoxaparin as Treatment of Covid 19 - Full Text View - ClinicalTrials.gov, (n.d.). https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04425863 (accessed November 10, 2021)."},{"key":"10.1016\/j.steroids.2022.109102_b0645","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/j.cmi.2022.02.031","article-title":"Inhaled ciclesonide for outpatient treatment of COVID-19 in adults at risk of adverse outcomes: a randomised controlled trial (COVERAGE)","volume":"28","author":"Duvignaud","year":"2022","journal-title":"Clin. Microbiol. Infect."},{"issue":"1","key":"10.1016\/j.steroids.2022.109102_b0650","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-09809-2","article-title":"Characterization, in-silico, and in-vitro study of a new steroid derivative from Ophiocoma dentata as a potential treatment for COVID-19","volume":"12","author":"Abd El Hafez","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.steroids.2022.109102_b0655","unstructured":"Coronavirus disease (COVID-19), (n.d.). https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019?gclid=CjwKCAiA1aiMBhAUEiwACw25MWtzNki49mrpkfAg-tlmOgcimhu9z5xbyFk3kkAu1qwhObpKDjbwQhoCbyQQAvD_BwE (accessed November 10, 2021)."},{"key":"10.1016\/j.steroids.2022.109102_b0660","unstructured":"Therapeutics and COVID-19: living guideline, (n.d.). https:\/\/www.who.int\/publications\/i\/item\/WHO-2019-nCoV-therapeutics-2021.2 (accessed August 1, 2021)."}],"container-title":["Steroids"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X22001404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0039128X22001404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,22]],"date-time":"2025-09-22T10:09:06Z","timestamp":1758535746000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0039128X22001404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":132,"alternative-id":["S0039128X22001404"],"URL":"https:\/\/doi.org\/10.1016\/j.steroids.2022.109102","relation":{},"ISSN":["0039-128X"],"issn-type":[{"value":"0039-128X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corticosteroids: A boon or bane for COVID-19 patients?","name":"articletitle","label":"Article Title"},{"value":"Steroids","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.steroids.2022.109102","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"109102"}}